2017 China Biopharmaceutical Industry Development Blue Book Officially Released: Focusing on Industry Development Pathways and Experience

2018Year8Month6Day,Firestone CreationOfficially Released2017Annual Blue Book on the Development of China's Biopharmaceutical Industry, compiled and authored by HSBC Innovation Research, utilizing HSBC Innovation's independently developedSpider Intelligent Data Source Construction System andDarwin Data Intelligence Processing Engine: Systematically researching and analyzing the current status and trends of the biopharmaceutical industry, and mapping out the development pathways for key global biopharmaceutical clusters and representative domestic industrial parks.Proposing Recommendations for the Development of China’s Biopharmaceutical Industry to Provide Guidance and Reference for Industrial Regulatory Authorities at All Levels and Industry Practitioners。

The Blue Book points out,The global biopharmaceutical market is exhibiting robust growth trends that significantly outpace the rate of global economic expansion., the biopharmaceutical industry is poised to enter a golden age of development, driven by the dual forces of technological advancement and growing demand. With intensifying global competition, both developed and emerging nations are significantly increasing their investments. Large enterprises are acquiring smaller ones, further boosting market concentration, while innovation in frontier biotechnology fields remains exceptionally vibrant.

Based on research into the development advantages and successful experiences of key global biopharmaceutical clusters, such as those in the Boston area of the United States, Israel, and Japan, it has been identified that, as a talent-intensive and knowledge-intensive industry,The biopharmaceutical industry has an inherent genetic predisposition for regional cluster development.. In the future, as countries around the world elevate biomedicine to a national strategic priority, biomedical industry clusters will accelerate their development, driving the effective aggregation of social resources. This will, in turn, promote highly coordinated development across the entire industry chain, reduce the risks associated with biopharmaceutical innovation and entrepreneurship, and enhance the efficiency of product commercialization.

From a domestic perspective, the biomedical industry is primarily concentrated in the Yangtze River Delta, the Pearl River Delta, and the Bohai Rim regions. Among these, key hubs include the Beijing Zhongguancun National Independent Innovation Demonstration Zone, Zhangjiang Pharma Valley, and the Suzhou BioBAY (BioBAY), industrial parks such as Wuhan Optics Valley Bio-city have become the most representative and advanced biopharmaceutical industry clusters in China.

By reviewing the development models of advanced domestic industrial parks, it is evident that the development model of the biopharmaceutical industry is dynamically composed of elements such as technology, market, talent, capital, enterprises, and government. How to highlight innovation-driven growth and maximize the value of industrial services are key issues that need to be addressed in industrial development. Therefore,The Blue Paper focuses on Zhangjiang Pharma Valley and the Suzhou BioBAY (BioBAY) as a typical case, analyzing the development models and pathways for fostering the biopharmaceutical industry in the two major parks, thereby revealing their value contributions to the innovative development of China’s biopharmaceutical industry.

Finally, based on the characteristics and development trends of the biopharmaceutical industry, and drawing on the successful experiences of global biopharmaceutical industry clusters as well as the environment and features of China’s industrial development,The Blue Paper onCountermeasures and Recommendations for the Industrial Development of China’s Biopharmaceutical Parks from Three Key Dimensions: “Specialized Clusters,” “Technological Innovation,” and “Financial Support”：

1、Strengthen macro-level top-down design and build distinctive industrial clusters: Strengthen coordinated planning and layout to achieve differentiated development; establish regional specialized industrial parks to foster distinctive industries; cultivate key regional competitive brands to enhance brand influence;

2, Build an Industrial Innovation System and Elevate the Level of Industrial Development: Establish an enterprise-led, market-oriented technological innovation system that integrates industry, academia, and research, strengthening the guiding role of scientific and technological innovation; enhance the innovation ecosystem to ensure the effective translation of innovative achievements into practical applications;

3, Increase financial support to ensure the development of technological innovation: Strengthen fiscal support and guidance to improve project effectiveness; refine the financial support system and enhance support for small and medium-sized innovative enterprises.

This Blue Book was compiled by Huoshi Creation, withWith the mission of “Accelerating Medical and Healthcare Innovation and Entrepreneurship for Universal Access to Healthy Living,” and grounded in comprehensive data and advanced algorithmic models, we have pioneered the world’s first Big Health Industry Brain. This platform empowers governments, industrial parks, life sciences and healthcare enterprises, and financial institutions, aiming to leverage data and intelligent insights to analyze, strategize, and drive the development of the industry.The compilation of this Blue Book has received strong support from numerous biopharmaceutical parks in China. In addition, Deloitte, one of the Big Four accounting firms worldwide, has provided valuable insights and recommendations for its preparation.

（Access Path for the Blue Book:PCEndOpen the Special Topic Page——www.hsmap.com/#/bulebook, click "Download Full Text of the Blue Book" at the bottom)